MESSAGE FROM THE DIRECTOR
Stan Gerson, MD
Director, Case CCC
Dear Cancer Center Members:
As you already know, the Cancer Center Annual Scientific Retreat is only a few weeks away. We are working right now to put all the details into place to ensure this two-day event is a success. Now is the time for you to adjust your schedules for July 10-11, and free up the entire Thursday evening through Friday evening to attend.
We already have many people registered, but there are still some members who have not responded. For those people and our new members, I want to remind you of both the value and impact of the retreat. This is a time to showcase our members and their research, to allow for dialogue and discussion, and to plan our next initiatives, recruitments, and expand our focus.
As a consortium center this retreat offers an additional opportunity to meet other members and discuss cancer research with colleagues across the institutions. It is also a chance to meet new members, forge new collaborations, and enhance the quality of science that we produce.
If you have not already done so, please register to attend. Your presence is very important, and your engagement and spirit is what makes our Center work.
Finally, I encourage all students, fellows and postdocs to participate in the poster session on Friday evening. It is always satisfying to witness the excitement of the next generation of cancer researchers. Plus, monetary prizes will be awarded!
I look forward to seeing you all at the retreat!
- Highlight and introduction of new members, including a new member poster session
- Keynote Address by Kevin Shannon, MD (UCSF):Preclinical Models to Test Strategies for Targeting Oncogenic Ras
- Full line-up of scientific talks by Cancer Center members followed by panel Q&A: Emerging Topics and Trends; Cancer Signaling and Drug Resistance; Cancer Genomics & Population Sciences; Experimental Therapeutics; Highlight on Innovative Awards
- Mid-day scientific program breakouts to discuss new initiatives, collaborations, and requests for Cancer Center support through research pilot project and core resources
- Students, postdoc and fellow poster competition. Submit abstracts by June 27. Monetary prizes will be awarded.
CASE CCC IN THE NEWS
Oral cancer study underway at CWRU, University Hospitals; new diagnostic test being researched
The Plain Dealer - June 13, 2014
A test being developed at Case Western Reserve University may someday be able to predict if someone will get oral cancer, as well as detect the disease much earlier...The notion of hBD-3 being part of a family of proteins was being pursued in the early 2000s by different research groups across the country, who discovered it in different parts of the body. CWRU researchers discovered it in the oral cavity, in saliva, the lining of the mouth and in pre-cancerous tissues there, said Dr. Aaron Weinberg, associate dean and chair of the Department of Biological Sciences at the dental school. Weinberg, the study's lead investigator, is working with Dr. Chad Zender, a head and neck surgeon at UH's Ear, Nose & Throat Institute. Head and neck cancer patients are getting younger, said Zender, who treats benign and cancerous lesions of the mouth and throat.
RESEARCH HIGHLIGHTS/MEMBER NEWS
Peter de Blank Inaugural Winner of Francis S. Collins Scholar Award
Peter de Blank, MD is one of two early career physician-scientists named inaugural winners of the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research, sponsored by the Neurofibromatosis Therapeutic Acceleration Program (NTAP) at Johns Hopkins University. The program will create a community of expert clinician-scientists and groom them to be leaders in neurofibromatosis type 1 (NF1) research and clinical care. The awards were presented at a ceremony last week at the Whittemore House in Washington, D.C.
Cancer Drug Boosts Levels of Vascular-Protective Gene, KLF2
Case Western Reserve University researchers have discovered that an existing drug used to help cancer patients has the potential to protect thousands of others from the often-deadly impact of vascular clots.
In 2008, the Food and Drug Administration approved bortezomib (Velcade) to treat multiple myeloma, which is a type of bone cancer and mantle cell lymphoma – a particularly aggressive form of non-Hodgkin lymphoma. In addition to attacking cancer cells, the drug has been shown to help prevent clot development common to many forms of the disease.
As hematologist Lalitha Nayak, MD, an assistant professor of medicine, reports in the June 12 edition of the journal "Blood," the anti-thrombotic effects of bortezomib are determined by KLF2, part of a family of Kruppel-like factors – master regulators of vascular health.
"We thought that if we could figure out how bortezomib protects against thrombosis," Nayak explained, "we might be closer to understanding why our patients develop blood clots and what could be done to help them."
She is also a member of the Mukesh Jain, MD, Laboratory at Case Western Reserve University, so she was also well aware of the laboratory's work in Kruppel-like factors. KLF2 specifically is a protein in the Kruppel-like gene family of transcription factors that prevents clot formation in the body's major blood vessels. (Transcription factor is a protein that controls the flow of genetic information that provides instructions to our bodies on how to function.)
"Work from our laboratory during the past decade has established Kruppel-like factors as nodal regulators of vascular health," said Jain, cardiologist and professor of medicine. "It was a good educated guess by Dr. Nayak that bortezomib's positive effect on vascular function was linked to a member of this family."
Limited Submission: Gabrielle's Angel Foundation
Gabrielle's Angel Foundation has invited the Case CCC to submit two applications (1 conventional and 1 integrative) for its annual Medical Research Awards. Eligible candidates must have their MD or PhD degree and currently hold a junior faculty position at a 501(c)(3) teaching research institution. Applicants must also currently be an Assistant Professor, hold a tenure track position, and have spent no more than five years in their current position.
Interested candidates should submit a one-page LOI to Kristin Waite (firstname.lastname@example.org) by Wednesday, June 25, 2014.
Internal LOI Deadline: June 25
External Application Deadline: August 15
AIDS and Cancer Specimen Resource
The AIDS and Cancer Specimen Resource (ACSR) is pleased to announce the ACSR Young Investigator Pilot Award. The ACSR Young Investigator Pilot Award is targeted toward junior investigators and faculty with innovative ideas for clinical and/or behavioral-epidemiological HIV-related research that utilizes ACSR's annotated biospecimens. Awards are intended for pilot work to show feasibility and/or to generate preliminary data that will support efforts for future funding of larger projects.
Deadline: August 1
Lymphoma Research Foundation
The Lymphoma Research Foundation (LRF) seeks proposals for the following opportunities:
Adolescent/Young Adult Cooperative Group Correlative Studies Grant: Applications to this initiative must be an adjunct to a major NCI cooperative group research project in lymphoma. Projects should also relate to work in the clinical setting and/or involve primary lymphoma patient samples. All principal investigators holding an academic faculty appointment at non-profit organizations or public or private institutions such as universities, colleges, hospitals, and laboratories, may apply.
Deadline: September 3
The LRF Clinical Investigator Career Development Grant Program is designed to support physician investigators at the level of advanced fellow or junior faculty member who will contribute to the development of new lymphoma therapies and diagnostic tools. Eligible investigators must have no greater than five years of experience beyond completion of their fellowship or post-doctoral training (the five year limit may be non-sequential in cases of interruptions for pregnancy or illness).
Deadline: September 3
The Lymphoma Research Foundation Lymphoma Clinical Research Mentoring Program (LCRMP) is an education and mentoring program for fellows and junior faculty with a focus in clinical research in the field of non-Hodgkin and Hodgkin lymphoma. The program is two years in length and offers a broad education on clinical research and career development as well as managing career and quality of life issues.
Deadline: September 3
The LRF Postdoctoral Fellowship Grant is designed to support investigators at the level of advanced fellow, postdoctoral researcher, or junior faculty member in laboratory or clinic based research with results and conclusions that must be clearly relevant to the treatment, diagnosis or prevention of Hodgkin and/or non-Hodgkin lymphoma.
Deadline: September 3
AACR Scholar-in-Training Awards: Other Conferences and Meetings
The AACR offers Scholar-in-Training Awards to enhance the education and training of early career scientists by providing financial support for their attendance at AACR conferences and meetings. These awards are provided to offset a portion of the registration, travel and subsistence expenses incurred in attending these programs. The number of awards available, award amounts and application requirements vary by conference.
MARK YOUR CALENDARS
Call for Abstracts: Case CCC Annual Scientific Retreat
There is still time to register to attend this year's Annual Case CCC Scientific Retreat, July 10-11, 2014. On Thursday, July 10 keynote speaker Kevin Shannon, MD from UCSF will kick-off the event with his presentation, Preclinical Models to Test Strategies for Targeting Oncogenic Ras. New this year, there will be discussion of new members and their research, including poster presentations during a cocktail reception reception.
The retreat will continue Friday, July 11 at Corporate College East. We have a full scientific line-up of talks from Cancer Center members: Emerging Topics and Trends; Cancer Signaling and Drug Resistance; Cancer Genomics & Population Sciences; Experimental Therapeutics; Highlight on Innovative Awards.
A mid-day breakout for each scientific program to discuss new initiatives, collaborations, and requests for Cancer Center support through research pilot project and core resources will be one of the highlights of the day.
Core directors will also be available during breaks to meet with you to discuss how they can help you further your research.
Finally, we will once again have judged poster presentations by the next generation of cancer researchers. All trainees, fellows and students are encouraged to submit abstracts. Monetary prizes will be awarded.
Pre-registration to attend the retreat is required. The retreat is open to Cancer Center members, Core Facility Directors/Managers, and students, fellows or postdocs who present posters. See the retreat webpage for more information.
NCRM Cancer Stem Cell Conference
The first CWRU: National Center for Regenerative Medicine Cancer Stem Cell Conference will be held in Cleveland, August 17-20, 2014. This conference is guaranteed to have incredible research from a variety of backgrounds in the Cancer Stem Cell field, and will feature keynote speakers from over 25 different institutions from around the world.
Cleveland Clinic 2014 Medical Innovation Summit
Save the date for the 2014 Medical Innovation Summit: Cancer Treatment and Personalized Medicine, October 27-29, 2014. The Medical Innovation Summit provides an unrivaled perspective on the newest medical innovations and the financial drivers behind those innovations. The conference is recognized for providing singular insights, networking opportunities and actionable take away for all participants.
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Lung Cancer Research Foundation
American Cancer Society Clinical Research Professor
NIH BULLETIN – Notices and Funding Opportunities
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to Gillian Irwin at email@example.com.